When Is a Harm a Harm? Discordance between Patient and Medical Experts' Evaluation of Lung Cancer Screening Attributes.


Journal

Medical decision making : an international journal of the Society for Medical Decision Making
ISSN: 1552-681X
Titre abrégé: Med Decis Making
Pays: United States
ID NLM: 8109073

Informations de publication

Date de publication:
04 2021
Historique:
pubmed: 9 2 2021
medline: 26 11 2021
entrez: 8 2 2021
Statut: ppublish

Résumé

A shared decision-making (SDM) process for lung cancer screening (LCS) includes a discussion between clinicians and patients about benefits and potential harms. Expert-driven taxonomies consider mortality reduction a benefit and consider false-positives, incidental findings, overdiagnosis, overtreatment, radiation exposure, and direct and indirect costs of LCS as potential harms. To explore whether patients conceptualize the attributes of LCS differently from expert-driven taxonomies. Cross-sectional study with semistructured interviews and a card-sort activity. Twenty-three Veterans receiving primary care at a Veterans Affairs Medical Center, 55 to 73 y of age with 30 or more pack-years of smoking. Sixty-one percent were non-Hispanic African American or Black, 35% were non-Hispanic White, 4% were Hispanic, and 9% were female. Semistructured interviews with thematic coding. The proportion of participants categorizing each attribute as a benefit or harm and emergent themes that informed this categorization. In addition to categorizing reduced lung cancer deaths as a benefit (22/23), most also categorized the following as benefits: routine annual screening (8/9), significant incidental findings (20/23), follow-up in a nodule clinic (20/23), and invasive procedures (16/23). Four attributes were classified by most participants as a harm: false-positive (13/22), overdiagnosis (13/23), overtreatment (6/9), and radiation exposure (20/22). Themes regarding the evaluation of LCS outcomes were 1) the value of knowledge about body and health, 2) anticipated positive and negative emotions, 3) lack of clarity in terminology, 4) underlying beliefs about cancer, and 5) risk assessment and tolerance for uncertainty. Anticipating discordance between patient- and expert-driven taxonomies of the benefits and harms of LCS can inform the development and interpretation of value elicitation and SDM discussions.

Sections du résumé

BACKGROUND
A shared decision-making (SDM) process for lung cancer screening (LCS) includes a discussion between clinicians and patients about benefits and potential harms. Expert-driven taxonomies consider mortality reduction a benefit and consider false-positives, incidental findings, overdiagnosis, overtreatment, radiation exposure, and direct and indirect costs of LCS as potential harms.
OBJECTIVE
To explore whether patients conceptualize the attributes of LCS differently from expert-driven taxonomies.
DESIGN
Cross-sectional study with semistructured interviews and a card-sort activity.
PARTICIPANTS
Twenty-three Veterans receiving primary care at a Veterans Affairs Medical Center, 55 to 73 y of age with 30 or more pack-years of smoking. Sixty-one percent were non-Hispanic African American or Black, 35% were non-Hispanic White, 4% were Hispanic, and 9% were female.
APPROACH
Semistructured interviews with thematic coding.
MAIN MEASURES
The proportion of participants categorizing each attribute as a benefit or harm and emergent themes that informed this categorization.
KEY RESULTS
In addition to categorizing reduced lung cancer deaths as a benefit (22/23), most also categorized the following as benefits: routine annual screening (8/9), significant incidental findings (20/23), follow-up in a nodule clinic (20/23), and invasive procedures (16/23). Four attributes were classified by most participants as a harm: false-positive (13/22), overdiagnosis (13/23), overtreatment (6/9), and radiation exposure (20/22). Themes regarding the evaluation of LCS outcomes were 1) the value of knowledge about body and health, 2) anticipated positive and negative emotions, 3) lack of clarity in terminology, 4) underlying beliefs about cancer, and 5) risk assessment and tolerance for uncertainty.
CONCLUSIONS
Anticipating discordance between patient- and expert-driven taxonomies of the benefits and harms of LCS can inform the development and interpretation of value elicitation and SDM discussions.

Identifiants

pubmed: 33554740
doi: 10.1177/0272989X20987221
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

317-328

Auteurs

Marilyn M Schapira (MM)

The Center for Health Equity Research and Promotion (CHERP) at the Michael J. Crescenz Veterans Affairs (VA) Medical Center, Philadelphia, PA, USA.
Division of General Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Keri L Rodriguez (KL)

CHERP, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.
Department of Medicine, Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Sumedha Chhatre (S)

The Center for Health Equity Research and Promotion (CHERP) at the Michael J. Crescenz Veterans Affairs (VA) Medical Center, Philadelphia, PA, USA.
The Department of Psychiatry, the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Liana Fraenkel (L)

VA Connecticut Healthcare System, West Haven, CT, USA.
Yale University School of Medicine, New Haven, CT, USA.

Lori A Bastian (LA)

VA Connecticut Healthcare System, West Haven, CT, USA.
Yale University School of Medicine, New Haven, CT, USA.

Jeffrey D Kravetz (JD)

VA Connecticut Healthcare System, West Haven, CT, USA.
Yale University School of Medicine, New Haven, CT, USA.

Onur Asan (O)

The Stevens Institute of Technology, School of Systems and Enterprises, Hoboken, NJ, USA.

Scott Akers (S)

Department of Radiology, The Michael J. Crescenz VA Medical Center and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Anil Vachani (A)

The Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.
Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Jason M Prigge (JM)

The Center for Health Equity Research and Promotion (CHERP) at the Michael J. Crescenz Veterans Affairs (VA) Medical Center, Philadelphia, PA, USA.

Jessica Meline (J)

The Center for Health Equity Research and Promotion (CHERP) at the Michael J. Crescenz Veterans Affairs (VA) Medical Center, Philadelphia, PA, USA.

Jennifer V Ibarra (JV)

VA Connecticut Healthcare System, West Haven, CT, USA.

Barbara Corn (B)

VA Connecticut Healthcare System, West Haven, CT, USA.

Dana Kaminstein (D)

The Center for Health Equity Research and Promotion (CHERP) at the Michael J. Crescenz Veterans Affairs (VA) Medical Center, Philadelphia, PA, USA.
Organizational Dynamics, Liberal and Professional Studies, School of Arts & Sciences, University of Pennsylvania, Philadelphia, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH